Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.

Oncotarget - 30 Mar 2015

Martin-Castillo Begoña, Lopez-Bonet Eugeni, Buxó Maria, Dorca Joan, Tuca-Rodríguez Francesc, Ruano Miguel Alonso, Colomer Ramon, Menendez Javier A

Abstract excerpt

There is an urgent need to refine the prognostic taxonomy of HER2+ breast carcinomas and develop easy-to-use, clinic-based prediction algorithms to distinguish between good- and poor- responders to trastuzumab-based therapy. Building on earlier studies suggesting that HER2+ tumors enriched with molecular and morpho-immunohistochemical features classically ascribed to basal-like tumors are highly aggressive and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Kaplan-Meier Estimate

Share to Keratin-5

Share to Keratin-6

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 25742793
DOI: 10.18632/oncotarget.3106
PMCID: PMC4466672

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.PMID 25742793Read ↗

Prognostic value of basal phenotype in HER2-overexpressing breast cancer.Semantic proximity Read ↗

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.Semantic proximity Read ↗

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin)Semantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.Semantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

The Distinctive Nature of HER2-Positive Breast CancersSemantic proximity Read ↗

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.Semantic proximity Read ↗

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.Semantic proximity Read ↗

Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of OutcomeSemantic proximity Read ↗

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerSemantic proximity Read ↗

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.